ArticleBMC cancer2025

A comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohort.

Nihanthy D Sreenath et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.